Outcomes of total arterial revascularization with skeletonized bilateral internal mammary artery: a prospective randomized trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003294

Enrollment

Unknown

Registered

2013-06-28

Start date

2013-07-08

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

A:total arterial revascularization with skeletonized bilateral internal mammary artery

B:Left ateral internal mammary + Great saphenous vein bridge Coronary artery bypass

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with isolated coronary artery disease scheduled for coronary artery bypass grafts in the condition that conservative treatment is invalid or indication for surgery is evident; 2. Aged 18-75 years, male or female; 3. patients suitable to accept either in situ total arterial revascularization or conventional LIMA+SVG CABG; 4. Patients willing to sign the informed consent of this study; 5. patients with no participations in other clinical trials.

Exclusion criteria

Exclusion criteria: 1. Patients with acute MI(7.5%; 7. FEV1 35; 9. Allens Test(-); 10. LVDd>75mm or LVEF=25%); severe lung function injury; abnormal outcomes of blood gas analysis with those contraindicated to lung function; severe multiple organs dysfunction); 12. Patients participating in any other clinical trials; 13. Patients unwilling to sign the informed consent of this study; 14. Patients require to withdraw the informed consent; 15. Patients not matched to other inclusion standards.

Design outcomes

Secondary

Measure	Time frame
operation duration (min);CPB time (min);cross-clamp time (min);ICU stay (days);ventilation time (hours);hospital stay (days);blood transfusion;drainage (ml);preoperative CAG;postoperative coronary artery CTA;HbA1c;TTE;CK;CK-MB;cTnT;lung function;S100B;NSE;CRP;SIRS;SAQ;NHYA evaluation of cardiac function;3 months postoperative CCS angina evaluation;ECG;1 year postoperative CAG;1 year postoperative coronary artery CTA;preoperative EQ-5D scale;3 months postoperative EQ-5D scale;6 months postoperative EQ-5D scale;1 year postoperative EQ-5D scale;preoperative SF-36 scale;3 months postoperative EQ-5D scale;6 months postoperative SF-36 scale;1 year postoperative SF-36 scale;	—

Measure

Time frame

operation duration (min);CPB time (min);cross-clamp time (min);ICU stay (days);ventilation time (hours);hospital stay (days);blood transfusion;drainage (ml);preoperative CAG;postoperative coronary artery CTA;HbA1c;TTE;CK;CK-MB;cTnT;lung function;S100B;NSE;CRP;SIRS;SAQ;NHYA evaluation of cardiac function;3 months postoperative CCS angina evaluation;ECG;1 year postoperative CAG;1 year postoperative coronary artery CTA;preoperative EQ-5D scale;3 months postoperative EQ-5D scale;6 months postoperative EQ-5D scale;1 year postoperative EQ-5D scale;preoperative SF-36 scale;3 months postoperative EQ-5D scale;6 months postoperative SF-36 scale;1 year postoperative SF-36 scale;

—

Primary

Measure	Time frame
mortality;grafts patency;complications;	—

Countries

China

Contacts

Public ContactLai, Wei

wei.lai@zs-hospital.sh.cn+86 13818176656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026